Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

RASBURICASE vs REGORAFENIB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

RASBURICASE vs REGORAFENIB: Safety Overview

Metric RASBURICASE REGORAFENIB
Total FAERS Reports 885 9,441
Deaths Reported 167 1,869
Death Rate 18.9% 19.8%
Hospitalizations 412 3,363
Average Patient Age 51.8 yrs 62.2 yrs
% Female Patients 36.3% 39.9%
FDA Approval Date N/A Jan 13, 2025
Manufacturer Sanofi-Aventis U.S. LLC Bayer HealthCare Pharmaceuticals Inc.
Route N/A ORAL
Marketing Status Prescription Prescription